Program Description
Non-alcoholic steatohepatitis (NASH) is a serious, progressive form of non-alcoholic fatty liver disease that is caused by excessive fat accumulation in the liver that induces chronic inflammation. With no current FDA-approved therapies for this progressive disease, the first-line management in NASH focuses on nonpharmacologic efforts and lifestyle modification strategies, such as addressing obesity, controlling diabetes, and fatty liver disease, primarily through sustained weight loss and exercise. However, these approaches alone have not reduced the increasing incidence of NASH, leaving patients with an important unmet need for therapy. This program will outline the growing body of evidence demonstrating the potential place in therapy of new and investigational agents that address the underlying pathophysiology of NASH with liver fibrosis to halt or reverse disease progression. An overview of the pathophysiology, risk factors, classic signs, and the current recommendations for the management of NASH along with a discussion of the pharmacist’s role in counseling patients on these agents and lifestyle modifications to reduce risk will be presented.
Target audience: Managed care pharmacists, specialty pharmacists
Type of activity: Application
Release date: May 18, 2023
Expiration date: May 18, 2024
Time to complete activity: 1.5 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the incidence, risk factors, clinical presentation, associated comorbidities, complications, and impact of non-alcoholic steatohepatitis (NASH) on patients’ health-related quality of life
- Employ the current guideline recommendations for the management of NASH
- Analyze the efficacy and safety of new agents and novel therapies under investigation for the treatment of NASH including mechanisms of action, administration, potential adverse effects, and monitoring parameters
- Illustrate the role of the pharmacist in educating patients about NASH and current and emerging management options
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Vice-Chair & Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington
Sarah Visintainer, PharmD, BCGP, BCMTMS, CSP
Senior Clinical Pharmacist
Shields Health Solutions
Stoughton, Massachusetts
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-222-H01-P. The activity is available for CE credit through May 18, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, has the following financial relationships with commercial interests to disclose:
Consultant: Sanofi, Bayer, Boehringer Ingelheim, Eli Lilly
Speakers Bureau: Dexcom
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Sarah Visintainer, PharmD, BCGP, BCMTMS, CSP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms